Quidel Corporation : Quidel to Hold First Quarter 2012 Financial Results Conference Call on April 25, 2012
04/13/2012| 03:33pm US/Eastern
Recommend:
SAN DIEGO, CA, Apr 13, 2012 (MARKETWIRE via COMTEX) -- Quidel
Corporation (NASDAQ: QDEL), a leading provider of rapid
diagnostic testing solutions and cellular-based virology
assays, will release first quarter 2012 financial results
after market close on Wednesday, April 25, 2012.
Following the release of results, Douglas Bryant, president
and chief executive officer, and Randy Steward, chief
financial officer, will host an investment community
conference call beginning at 5:00 p.m. Eastern Time (2:00
p.m. Pacific Time) to discuss first quarter results and
answer questions. During the conference call, the company
will also discuss business and financial developments and
trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
To participate in the live call by telephone from the U.S.,
dial 866-804-6923, or from outside the U.S. dial
857-350-1669, and enter the pass code 22042976.
A live webcast of the call can be accessed at http://www.quidel.com, and the
Web site replay will be available for 14 days. The telephone
replay will be available for 48 hours beginning at 8:00 p.m.
Eastern Time (5:00 p.m. Pacific Time) on April 25 by dialing
888-286-8010 from the U.S., or 617-801-6888 for international
callers, and entering pass code 62684861.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well
being of people around the globe through the development of
diagnostic solutions that can lead to improved patient
outcomes and provide economic benefits to the healthcare
system. Marketed under the QuickVue(R), D3(R) Direct
Detection and Thyretain(TM) leading brand names, as well as
under the new Sofia(R) and Quidel Molecular(TM) brands,
Quidel's products aid in the detection and diagnosis of
many critical diseases and conditions, including, among
others,
influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy,
thyroid disease and
fecal occult blood. Quidel's research and development
engine is also developing a continuum of diagnostic solutions
from advanced lateral-flow and direct fluorescent antibody to
molecular diagnostic tests to further improve the quality of
healthcare in physicians' offices and hospital and
reference laboratories.www.quidel.com and Diagnostic
Hybrids at www.dhiusa.com.
Quidel Contact:
Quidel Corporation
Randy Steward
Chief Financial Officer
(858) 552-7931
Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
SOURCE: Quidel
distributed by
|
|
Recommend :
